Beyond PARP-POLθ as an anticancer target

Science. 2018 Mar 16;359(6381):1217-1218. doi: 10.1126/science.aar5149.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • DNA Breaks, Double-Stranded
  • DNA End-Joining Repair
  • DNA Polymerase theta
  • DNA Repair-Deficiency Disorders / drug therapy*
  • DNA Repair-Deficiency Disorders / genetics
  • DNA-Directed DNA Polymerase / metabolism*
  • Genes, BRCA1
  • Homologous Recombination
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Poly(ADP-ribose) Polymerases / metabolism*

Substances

  • Antineoplastic Agents
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases
  • DNA-Directed DNA Polymerase